Getting an Accurate Diagnosis: Testing and Imaging
At a Glance
PPNAD can be difficult to confirm because cortisol release may be intermittent and its tiny adrenal nodules often do not appear on CT or MRI. Diagnosis usually combines repeated cortisol testing, ACTH measurement, specialist evaluation, and genetic testing.
Because PPNAD is a rare and often cyclic disease, the path to a diagnosis requires repeated, validated hormone tests, clinical interpretation by an endocrinologist, and specialized imaging. Standard tests that work for other types of Cushing’s syndrome can sometimes produce confusing results, making an individualized approach essential to find the small, pigmented nodules hidden within the adrenal glands [1][2].
The Biochemical Evaluation
The first step is confirming that your body is producing too much cortisol and that the signal is coming directly from the adrenal glands, rather than the brain.
- ACTH Independence: In PPNAD, your adrenal glands pump out cortisol on their own. This causes your brain to stop producing ACTH (the “start” signal). Therefore, a feature of PPNAD is having high cortisol levels while your ACTH levels are suppressed (though the exact interpretation depends on the assay and timing) [3].
- The Problem with “Normal” Results: Because PPNAD can be cyclic, your cortisol might be high one week and normal the next [4]. If you have cyclic disease, doctors may need to repeat 24-hour urine tests or late-night salivary tests multiple times to “catch” the condition during an active cycle [5][1].
The Liddle Test: A Paradoxical Clue
In select cases, endocrinologists may use a 6-day Liddle test (an oral dexamethasone suppression test).
In most cases of Cushing’s syndrome, giving a synthetic steroid called dexamethasone will either lower your cortisol or keep it the same. In some patients with PPNAD, however, your cortisol levels can actually rise during the test [6].
This is called a paradoxical rise [7]. When this happens, it is thought to be because the mutation in the PRKAR1A gene makes the adrenal cells hypersensitive. Instead of shutting down, the nodules react to the test by increasing their cortisol production [8]. While a substantially larger urinary free cortisol increase (often around 50% in some literature) can support a PPNAD diagnosis, it is not pathognomonic, and thresholds vary by protocol [6][9]. This is a specialist-directed, optional test, and local protocols differ. Patients should not try to schedule or interpret dexamethasone testing independently.
Why Imaging Often “Misses” PPNAD
A common diagnostic pitfall is relying solely on a standard CT or MRI scan. In many patients with PPNAD, these scans appear completely normal [2].
- Micronodules: The nodules in PPNAD are tiny—usually only 1 to 4 millimeters [10]. They are often too small for standard imaging to see [11].
- Normal Gland Size: Unlike other adrenal diseases where the glands become large and bulky, the adrenal glands in PPNAD often stay a normal size [12].
- NP-59 Scintigraphy: In limited specialist centers, if CT or MRI is unrevealing and it would change treatment, doctors might consider a “functional” scan called NP-59 scintigraphy. This test uses radiation to show if both adrenal glands are overactive even when they look normal on a CT scan, but it is not a routine part of modern evaluation [2].
Distinguishing PPNAD from Similar Conditions
Your medical team must rule out other conditions that cause adrenal-based Cushing’s syndrome:
- BMAH (Bilateral Macronodular Adrenocortical Hyperplasia): In this condition, the nodules are large (usually over 1 cm) and easily seen on CT scans. It typically affects older adults (ages 40–60), whereas PPNAD often appears in children and young adults [11][13].
- McCune-Albright Syndrome (MAS): This is a genetic condition that can cause adrenal trouble very early in life (infancy). It is usually distinguished from PPNAD by other signs, such as large “cafe-au-lait” birthmarks or bone abnormalities [13][14].
The Role of Genetic Testing
Genetic testing is a cornerstone of evaluating Carney Complex. Roughly 70% to 80% of people with PPNAD have a mutation in the PRKAR1A gene [1][15].
- What if it’s negative?: A negative test does not rule out PPNAD. Some patients have “mosaicism,” where the mutation is only in some cells, or mutations in other less common genes like PRKACA [16][17] (though these may present differently).
- Family Impact: If a mutation is found, your doctor will likely recommend cascade testing for your close relatives to see if they are also at risk for PPNAD or other Carney Complex issues [1][18].
Components Your Endocrinologist May Consider
Rather than rigid prerequisites, diagnosis relies on clinical judgment using a combination of the following:
- [ ] Repeated appropriate testing confirming ACTH-independent cortisol excess (High cortisol + Suppressed ACTH).
- [ ] Evaluation of “diurnal rhythm” (whether cortisol stays high at night).
- [ ] A 6-day Liddle test to check for a paradoxical rise, if selected by a specialist.
- [ ] Conducted a physical exam for Carney Complex signs (skin spots/lentigines).
- [ ] Ordered PRKAR1A genetic sequencing and duplication/deletion analysis.
Common questions in this guide
Can PPNAD be present if one cortisol test is normal?
What does suppressed ACTH mean when PPNAD is suspected?
Can a CT or MRI scan miss PPNAD?
What does a paradoxical cortisol rise during the Liddle test mean?
Does a negative PRKAR1A test rule out PPNAD?
Why might someone with PPNAD have genetic testing for Carney complex?
Get notified when new evidence is published on pigmented nodular adrenocortical disease, primary, 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Integrated clinical-genetic-pathological analysis expands the phenotypic and molecular spectrum of PPNAD across carney complex and isolated forms.
Kuhn AW, Lerario AM, Charchar HL, et al.
European journal of endocrinology 2026; (195(2)):217-228 doi:10.1093/ejendo/lvag137.
PMID: 42543523 - 2
Hormonal, Radiological, NP-59 Scintigraphy, and Pathological Correlations in Patients With Cushing's Syndrome Due to Primary Pigmented Nodular Adrenocortical Disease (PPNAD).
Vezzosi D, Tenenbaum F, Cazabat L, et al.
The Journal of clinical endocrinology and metabolism 2015; (100(11)):4332-8 doi:10.1210/jc.2015-2174.
PMID: 26390100 - 3
Primary pigmented nodular adrenocortical disease (PPNAD): single centre experience.
Memon SS, Thakkar K, Patil V, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(4)):391-397.
PMID: 30875328 - 4
Factitious Cushing's Syndrome: A Diagnosis to Consider When Evaluating Hypercortisolism.
Pineyro MM, Redes L, De Mattos S, et al.
Frontiers in endocrinology 2019; (10()):129 doi:10.3389/fendo.2019.00129.
PMID: 30886602 - 5
Preventing Cushing Syndrome: Adrenalectomy in PDE11A-Positive Primary Pigmented Nodular Adrenocortical Disease.
Carling T, LaRue M, Lenz AM, et al.
JCEM case reports 2026; (4(2)):luaf329 doi:10.1210/jcemcr/luaf329.
PMID: 41694449 - 6
Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome.
Chen S, Li R, Lu L, et al.
Endocrine 2018; (59(1)):183-190 doi:10.1007/s12020-017-1436-9.
PMID: 29094256 - 7
Update on primary micronodular bilateral adrenocortical diseases.
Maillet M, Bourdeau I, Lacroix A
Current opinion in endocrinology, diabetes, and obesity 2020; (27(3)):132-139 doi:10.1097/MED.0000000000000538.
PMID: 32209819 - 8
PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease.
Bram Z, Louiset E, Ragazzon B, et al.
JCI insight 2016; (1(15)):e87958.
PMID: 27699247 - 9
Carney Syndrome Presented as a Pathological Spine Fracture in a 35-Year-Old Male.
Kiriakopoulos A, Linos D
The American journal of case reports 2018; (19()):1366-1369 doi:10.12659/AJCR.911962.
PMID: 30442879 - 10
Cushing Syndrome in Carney Complex: Clinical, Pathologic, and Molecular Genetic Findings in the 17 Affected Mayo Clinic Patients.
Lowe KM, Young WF, Lyssikatos C, et al.
The American journal of surgical pathology 2017; (41(2)):171-181 doi:10.1097/PAS.0000000000000748.
PMID: 27875378 - 11
Bilateral Adrenocortical Nodular Disease and Cushing's Syndrome.
Bouys L, Violon F, Louiset E, et al.
The Journal of clinical endocrinology and metabolism 2024; (109(10)):2422-2432 doi:10.1210/clinem/dgae419.
PMID: 38888184 - 12
Use of 3-Dimensional Volumetric Modeling of Adrenal Gland Size in Patients with Primary Pigmented Nodular Adrenocortical Disease.
Chrysostomou PP, Lodish MB, Turkbey EB, et al.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2016; (48(4)):242-246 doi:10.1055/s-0042-103686.
PMID: 27065461 - 13
Nonmalignant Adrenocorticotrophic Hormone-Independent Cushing's Syndrome in Pediatric Patients: A Retrospective Observational Cohort Study.
Hassan M, Samara-Boustani D, Besançon A, et al.
Hormone research in paediatrics 2026; (99(5)):718-729 doi:10.1159/000545265.
PMID: 40132568 - 14
Adrenocortical tumorigenesis: Lessons from genetics.
Kamilaris CDC, Hannah-Shmouni F, Stratakis CA
Best practice & research. Clinical endocrinology & metabolism 2020; (34(3)):101428 doi:10.1016/j.beem.2020.101428.
PMID: 32507359 - 15
The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.
Sun J, Ding L, He L, et al.
Frontiers in endocrinology 2024; (15()):1356870 doi:10.3389/fendo.2024.1356870.
PMID: 39006359 - 16
PRKACA constitutional duplication: a specific cause of primary pigmented nodular adrenocortical disease.
Vaduva P, Violon F, Chansavang A, et al.
European journal of endocrinology 2025; (193(6)):733-744 doi:10.1093/ejendo/lvaf255.
PMID: 41403049 - 17
First Somatic PRKAR1A Defect Associated With Mosaicism for Another PRKAR1A Mutation in a Patient With Cushing Syndrome.
Kamilaris CDC, Faucz FR, Andriessen VC, et al.
Journal of the Endocrine Society 2021; (5(4)):bvab007 doi:10.1210/jendso/bvab007.
PMID: 33644619 - 18
Phenotypic Variability in a Family with Carney Complex Accompanied by a Novel Mutation Involving PRKAR1A.
Kubo H, Tsurutani Y, Sugisawa C, et al.
The Tohoku journal of experimental medicine 2022; (257(4)):337-345 doi:10.1620/tjem.2022.J051.
PMID: 35732416
This page is for informational purposes only and is not medical advice. Your endocrinologist should interpret hormone results and determine which PPNAD tests or imaging are appropriate for you.